Facebook Linkedin RSS Twitter Youtube
Home 2024

Phase I clinical trials (Drug development)

Hubble Therapeutics Taps Andelyn to Manufacture Clinical Grade AAV for Eye Disorder Gene Therapy
Bioprocessing

Hubble Therapeutics Taps Andelyn to Manufacture Clinical Grade AAV for Eye Disorder Gene Therapy

AI in Drug Design: From Hype to Real-World Results
Artificial Intelligence

AI in Drug Design: From Hype to Real-World Results

Quell Therapeutics Taps eXmoor Pharma to Manufacture CAR-Tregs
Bioprocessing

Quell Therapeutics Taps eXmoor Pharma to Manufacture CAR-Tregs

Bertozzi’s TwoStep Therapeutics to Target Solid Tumors With Engineered Peptide Drug Delivery Vehicle
Cancer

Bertozzi’s TwoStep Therapeutics to Target Solid Tumors With Engineered Peptide Drug Delivery Vehicle

StockWatch: Biogen Q1 Results Beat Expectations, for a Change
Drug Discovery

StockWatch: Biogen Q1 Results Beat Expectations, for a Change

Insilico Targets MTAP Deleted Cancers with AI-Designed Candidate
Artificial Intelligence

Insilico Targets MTAP Deleted Cancers with AI-Designed Candidate

Dendritic Cell Vaccine Improves Survival Compared to Standard of Care in Phase I Trial for Glioblastoma
Cancer

Dendritic Cell Vaccine Improves Survival Compared to Standard of Care in Phase I Trial for Glioblastoma

Vaccines in Development
Infectious Diseases

Vaccines in Development

Evotec Expands Anti-HIV Antibody Deal with Advanced BioScience Laboratories
Bioprocessing

Evotec Expands Anti-HIV Antibody Deal with Advanced BioScience Laboratories

Roche to Acquire Telavant for Up-to-$7.25B, Adding IBD Antibody
Drug Discovery

Roche to Acquire Telavant for Up-to-$7.25B, Adding IBD Antibody

123...39Page 1 of 39
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.